

**Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase – Interim Reporting**

With disclosure dated December 19, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a third tranche of up to USD 70 million under the share repurchase program originally announced on January 31, 2018.

The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program in the time period from February 25, 2019 until and including March 1, 2019 amounts to 117,985 shares.

Shares were bought back as follows:

<b>Date</b>	<b>Number of Shares acquired</b>	<b>Average Price (EUR)</b>	<b>Purchased Volume (EUR)</b>
25 February 2019	23,236	34.3855	798,981.48
26 February 2019	23,561	33.9561	800,039.67
27 February 2019	23,826	33.5756	799,972.25
28 February 2019	23,850	33.5436	800,014.86
01 March 2019	23,512	34.0246	799,986.40
<b>Total</b>	<b>117,985</b>	<b>33.8941</b>	<b>3,998,994.65</b>

The underlying individual trades are published on the website of QIAGEN N.V. (<http://corporate.qiagen.com/investor-relations/share-information/share-buyback>).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from December 19, 2018 until and including March 1, 2019 amounts to 1,248,455 shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 5 March 2019

Managing Board

###

**Contacts:**

**QIAGEN**

**Investor Relations**

John Gilardi  
e-mail: [ir@qiagen.com](mailto:ir@qiagen.com)

+49 2103 29 11711

**Public Relations**

Dr. Thomas Theuringer  
e-mail: [pr@qiagen.com](mailto:pr@qiagen.com)

+49 2103 29 11826